Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC) - Episode 8

Lung LCNEC Disease Histology and Prognosis

,

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

EP. 1: Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro
EP. 2: An Overview of the Molecular Characterization of Lung LCNEC
EP. 3: The Pathological Diagnosis of Lung LCNEC
EP. 4: Biomarker Testing Strategies for Lung LCNEC
EP. 5: Biopsy Best Practices: Diagnosing Lung LCNEC
EP. 6: Lung LCNEC Diagnostic Challenges
EP. 7: A Multidisciplinary Approach to Managing Lung LCNEC
Now Viewing
EP. 8: Lung LCNEC Disease Histology and Prognosis
EP. 9: The Role of DLL3 in LCNEC of the Lung
EP. 10: Insights on the LANCE Pilot Study on Lung LCNEC
  • Given the limited therapeutic options for patients with lung LCNEC, what is your typical treatment approach?
    • What patient-specific factors do you consider to guide your first-line treatment selection?
  • Please share your thoughts on the ASCO 2024 retrospective studies examining first-line systemic treatment outcomes: 1. (Nassar et al, ASCO 2024); 2. (Matteson et al., ASCO 2024)
    • What are your key considerations for choosing a second-line treatment strategy?
    • How has the tarlatamab approval in SCLC(Ahn et al., NEJM 2023) impacted your treatment approach for patients with LCNEC?

Related Content:

Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC)
Insights on the LANCE Pilot Study on Lung LCNEC
The Role of DLL3 in LCNEC of the Lung
A Multidisciplinary Approach to Managing Lung LCNEC